SUV39H1

Mnemo Therapeutics Announces Publication in Cancer Discovery on Ablation of SUV39H1 for Long-Term Protection Against Solid Tumors

Retrieved on: 
Tuesday, November 7, 2023
Neoplasm, CAR, Mnemos EP, Therapy, Biotechnology, Lung cancer, SUV39H1, Immunotherapy, Gene, Memory, Longevity, Vaccine, Cancer Discovery (journal)

PARIS, Nov. 7, 2023 /PRNewswire/ -- Mnemo Therapeutics, a biotechnology company developing transformational immunotherapies, has announced a new preclinical study showing that CAR T cell memory differentiation and persistence can be enhanced by inactivating SUV39H1, an enzyme (histone methyltransferase) that epigenetically regulates and represses memory-associated genes. The paper, published in Cancer Discovery, is titled "SUV39H1 Ablation Enhances Long-Term CAR-T Function in Solid Tumors."

Key Points: 
  • The paper, published in Cancer Discovery, is titled "SUV39H1 Ablation Enhances Long-Term CAR-T Function in Solid Tumors."
  • SUV39H1-inactivated CAR T cells promote long-term protection against tumor relapses and rechallenges, demonstrated in mouse models of lung cancer and other solid tumors.
  • "T cell exhaustion and lack of persistence impede the long-term success of immunotherapy treatments for tumors," said Mnemo Chief Executive Officer Robert LaCaze.
  • SUV39H1 Ablation Enhances Long-Term CAR-T Function in Solid Tumors.

Mnemo Therapeutics Appoints Christine Foster, Ph.D. and Co-Founder Sebastian Amigorene, Ph.D. to Key Leadership Roles

Retrieved on: 
Wednesday, November 30, 2022
Growth, GlaxoSmithKline, SUV39H1, Science, Laboratory, Ionis Pharmaceuticals, Intellia Therapeutics, University, Pharmacology, Multimedia, Responsibility, Therapy, Biotechnology, Degenerative disease, Sebastian Amigorena, Neuroscience, Senior, Acceleron Pharma, Foster, Brandeis University, Regeneron Pharmaceuticals, Teva Pharmaceuticals, Cancer, Research, Memory, Cell biology, CNRS, Immunotherapy, University of Massachusetts Medical School, Mnemos EP, Management, Pharmaceutical industry, Novartis, Princeton University, Immunology, Pfizer

Mnemo also announced the appointment of Scientific Co-Founder Sebastian Amigorena, Ph.D. as Senior Vice President, Immunology.

Key Points: 
  • Mnemo also announced the appointment of Scientific Co-Founder Sebastian Amigorena, Ph.D. as Senior Vice President, Immunology.
  • "Christine brings a stellar history building meaningful value for biopharmaceutical companies by guiding business development and establishing strategic collaborations," said Mnemo Chief Executive Officer Robert LaCaze.
  • "I am thrilled to contribute to the science and innovation taking place at Mnemo Therapeutics," Foster said.
  • To learn more, visit https://mnemo-tx.com and follow Mnemo Therapeutics on Twitter (@MnemoTx) and LinkedIn.

Mnemo Therapeutics Launches RHU Project in Collaboration with Leading European Research Partners, Institut Curie and MEARY Cell and Gene Therapy Center, AP-HP

Retrieved on: 
Monday, June 13, 2022
Leadership, RHU, Cell, Research, Biotechnology, Responsibility, Gene, SUV39H1, Multimedia, Saint Louis Hospital (Bangkok), Therapy, Memory, Patient, Hospital, Technology, Laboratory, Immune system, Phenotype, Curie Institute (Paris), AP-HP, Cancer, Pharmaceutical industry, Vaccine, Mnemos EP, Princeton University

PARIS, June 13, 2022 /PRNewswire/ -- Mnemo Therapeutics, a biotechnology company developing transformational immunotherapies, today announced the kick-off of their participation in the prestigious Hospital-University Research in Health (RHU) program. Designed by France's National Research Agency, the RHU funding supports cutting-edge research and cross-institutional collaborations, bringing together academia, businesses, and hospitals to push the boundaries of what is possible in healthcare.

Key Points: 
  • Designed by France's National Research Agency, the RHU funding supports cutting-edge research and cross-institutional collaborations, bringing together academia, businesses, and hospitals to push the boundaries of what is possible in healthcare.
  • Among them, receiving close to 10 million euros, is the EpCART project.
  • "We are honored to be named a laureate for this prestigious initiative and work alongside our long-standing partners at Institut Curie, as well as the MEARY Cell and Gene Therapy Center at Saint-Louis Hospital, AP-HP," said Mnemo CEO, Robert LaCaze.
  • Over the next five years, the EpCART project will seek to clinically validate this technology as an autologous therapy.